Alembic Pharma reported a 12% YoY rise in Q2FY25 net profit to Rs 153 crore, driven by strong domestic and US market sales. Revenues grew 3% to Rs 1648 crore, while EBITDA declined 6%, with margins at 15.6%
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
